Pandemic Influenza Vaccine H5N1 Baxter AG


pandemic influenza vaccine (H5N1) (whole virion, inactivated, prepared in cell culture)

This medicine is now withdrawn from use in the European Union.


The marketing authorisation for Pandemic Influenza Vaccine H5N1 Baxter has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 13/09/2023

Authorisation details

Product details
Pandemic Influenza Vaccine H5N1 Baxter AG
Agency product number
Active substance
influenza vaccine (whole virion, inactivated) containing antigen of: A/Vietnam/1203/2004 (H5N1)
International non-proprietary name (INN) or common name
pandemic influenza vaccine (H5N1) (whole virion, inactivated, prepared in cell culture)
Therapeutic area (MeSH)
  • Influenza, Human
  • Immunization
  • Disease Outbreaks
Anatomical therapeutic chemical (ATC) code
Exceptional circumstancesExceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see Pre-authorisation guidance.

Publication details
Marketing-authorisation holder
Resilience Biomanufacturing Ireland Limited
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Resilience Biomanufacturing Ireland Limited
Shelbourne Buildings 2
Cramptom Avenue
Dublin 4
D04 W3V6

Product information

01/02/2023 Pandemic Influenza Vaccine H5N1 Baxter AG - EMEA/H/C/001200 - IAIN/0032

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

Prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with official guidance.

Assessment history

How useful was this page?

Add your rating
1 rating